{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:19:18Z","timestamp":1788369558276,"version":"build-2803163510"},"reference-count":172,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypoxia, a condition of oxygen deprivation, is considered a hallmark of tumor microenvironment regulating several pathways and promoting cancer progression and resistance to therapy. Semaphorins, a family of about 20 secreted, transmembrane and GPI-linked glycoproteins, and their cognate receptors (plexins and neuropilins) play a pivotal role in the crosstalk between cancer and stromal cells present in the tumor microenvironment. Many studies reported that some semaphorins are involved in the development of a permissive tumor niche, guiding cell-cell communication and, consequently, the development and progression, as well as the response to therapy, of different cancer histotypes, including melanoma.<\/jats:p>\n                  <jats:p>In this review we will summarize the state of art of semaphorins regulation by hypoxic condition in cancer with different origin. We will also describe evidence about the ability of semaphorins to affect the expression and activity of transcription factors activated by hypoxia, such as hypoxia-inducible factor-1. Finally, we will focus our attention on findings reporting the role of semaphorins in melanocytes transformation, melanoma progression and response to therapy. Further studies are necessary to understand the mechanisms through which semaphorins induce their effect and to shed light on the possibility to use semaphorins or their cognate receptors as prognostic markers and\/or therapeutic targets in melanoma or other malignancies.<\/jats:p>","DOI":"10.1186\/s13046-021-01929-3","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T10:04:35Z","timestamp":1618481075000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia"],"prefix":"10.1186","volume":"40","author":[{"given":"Elisabetta","family":"Valentini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Di Martile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3148-6096","authenticated-orcid":false,"given":"Donatella","family":"Del Bufalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"D\u2019Aguanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"issue":"24","key":"1929_CR1","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1242\/dev.125.24.5043","volume":"125","author":"D Bagnard","year":"1998","unstructured":"Bagnard D, Lohrum M, Uziel D, Puschel AW, Bolz J. Semaphorins act as attractive and repulsive guidance signals during the development of cortical projections. Development. 1998;125(24):5043\u201353.","journal-title":"Development"},{"issue":"6600","key":"1929_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/383525a0","volume":"383","author":"O Behar","year":"1996","unstructured":"Behar O, Golden JA, Mashimo H, Schoen FJ, Fishman MC. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. Nature. 1996;383(6600):525\u20138. https:\/\/doi.org\/10.1038\/383525a0.","journal-title":"Nature"},{"issue":"128","key":"1929_CR3","doi-asserted-by":"publisher","first-page":"re4","DOI":"10.1126\/stke.2002.128.re4","volume":"2002","author":"G Bismuth","year":"2002","unstructured":"Bismuth G, Boumsell L. Controlling the immune system through semaphorins. Sci STKE. 2002;2002(128):re4.","journal-title":"Sci STKE"},{"issue":"31","key":"1929_CR4","doi-asserted-by":"publisher","first-page":"11432","DOI":"10.1073\/pnas.0403969101","volume":"101","author":"E Castro-Rivera","year":"2004","unstructured":"Castro-Rivera E, Ran S, Thorpe P, Minna JD. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci U S A. 2004;101(31):11432\u20137. https:\/\/doi.org\/10.1073\/pnas.0403969101.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"42","key":"1929_CR5","doi-asserted-by":"publisher","first-page":"28074","DOI":"10.1074\/jbc.M804203200","volume":"283","author":"D Bae","year":"2008","unstructured":"Bae D, Lu S, Taglienti CA, Mercurio AM. Metabolic stress induces the lysosomal degradation of neuropilin-1 but not neuropilin-2. J Biol Chem. 2008;283(42):28074\u201380. https:\/\/doi.org\/10.1074\/jbc.M804203200.","journal-title":"J Biol Chem"},{"issue":"362","key":"1929_CR6","doi-asserted-by":"publisher","first-page":"362ra144","DOI":"10.1126\/scitranslmed.aaf9440","volume":"8","author":"M Oubaha","year":"2016","unstructured":"Oubaha M, Miloudi K, Dejda A, Guber V, Mawambo G, Germain MA, et al. Senescence-associated secretory phenotype contributes to pathological angiogenesis in retinopathy. Sci Transl Med. 2016;8(362):362ra144.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1929_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrrheum.2017.201","volume":"14","author":"M Nishide","year":"2018","unstructured":"Nishide M, Kumanogoh A. The role of semaphorins in immune responses and autoimmune rheumatic diseases. Nat Rev Rheumatol. 2018;14(1):19\u201331. https:\/\/doi.org\/10.1038\/nrrheum.2017.201.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"1929_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nrd4337","volume":"13","author":"T Worzfeld","year":"2014","unstructured":"Worzfeld T, Offermanns S. Semaphorins and plexins as therapeutic targets. Nat Rev Drug Discov. 2014;13(8):603\u201321. https:\/\/doi.org\/10.1038\/nrd4337.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1929_CR9","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1161\/CIRCRESAHA.115.303657","volume":"115","author":"NJ Boczek","year":"2014","unstructured":"Boczek NJ, Ye D, Johnson EK, Wang W, Crotti L, Tester DJ, et al. Characterization of SEMA3A-encoded semaphorin as a naturally occurring Kv4.3 protein inhibitor and its contribution to Brugada syndrome. Circ Res. 2014;115(4):460\u20139. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.303657.","journal-title":"Circ Res"},{"key":"1929_CR10","doi-asserted-by":"crossref","unstructured":"Fard D, Tamagnone L. Semaphorins in health and disease. Cytokine Growth Factor Rev. 2020.","DOI":"10.1016\/j.cytogfr.2020.05.006"},{"issue":"14","key":"1929_CR11","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1242\/dev.051318","volume":"138","author":"HL Goel","year":"2011","unstructured":"Goel HL, Bae D, Pursell B, Gouvin LM, Lu S, Mercurio AM. Neuropilin-2 promotes branching morphogenesis in the mouse mammary gland. Development. 2011;138(14):2969\u201376. https:\/\/doi.org\/10.1242\/dev.051318.","journal-title":"Development"},{"issue":"11","key":"1929_CR12","first-page":"3356","volume":"119","author":"F Maione","year":"2009","unstructured":"Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest. 2009;119(11):3356\u201372.","journal-title":"J Clin Invest"},{"issue":"2","key":"1929_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1593\/neo.111600","volume":"14","author":"HK Wong","year":"2012","unstructured":"Wong HK, Shimizu A, Kirkpatrick ND, Garkavtsev I, Chan AW, di Tomaso E, et al. Merlin\/NF2 regulates angiogenesis in schwannomas through a Rac1\/semaphorin 3F-dependent mechanism. Neoplasia. 2012;14(2):84\u201394. https:\/\/doi.org\/10.1593\/neo.111600.","journal-title":"Neoplasia"},{"issue":"10","key":"1929_CR14","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.15252\/emmm.201505551","volume":"7","author":"G Serini","year":"2015","unstructured":"Serini G, Tamagnone L. Bad vessels beware! Semaphorins will sort you out! EMBO Mol Med. 2015;7(10):1251\u20133. https:\/\/doi.org\/10.15252\/emmm.201505551.","journal-title":"EMBO Mol Med"},{"issue":"5","key":"1929_CR15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/CMR.0000000000000621","volume":"29","author":"AV Komina","year":"2019","unstructured":"Komina AV, Palkina NV, Aksenenko MB, Lavrentev SN, Moshev AV, Savchenko AA, et al. Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status. Melanoma Res. 2019;29(5):544\u20138. https:\/\/doi.org\/10.1097\/CMR.0000000000000621.","journal-title":"Melanoma Res"},{"key":"1929_CR16","doi-asserted-by":"publisher","unstructured":"Napolitano V, Tamagnone L. Neuropilins Controlling Cancer Therapy Responsiveness. Int J Mol Sci. 2019;20(8). https:\/\/doi.org\/10.3390\/ijms20082049.","DOI":"10.3390\/ijms20082049"},{"issue":"2","key":"1929_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ccr.2012.06.031","volume":"22","author":"L Tamagnone","year":"2012","unstructured":"Tamagnone L. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. Cancer Cell. 2012;22(2):145\u201352. https:\/\/doi.org\/10.1016\/j.ccr.2012.06.031.","journal-title":"Cancer Cell"},{"issue":"4","key":"1929_CR18","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.molmed.2019.01.010","volume":"25","author":"S Gurrapu","year":"2019","unstructured":"Gurrapu S, Tamagnone L. Semaphorins as regulators of phenotypic plasticity and functional reprogramming of Cancer cells. Trends Mol Med. 2019;25(4):303\u201314. https:\/\/doi.org\/10.1016\/j.molmed.2019.01.010.","journal-title":"Trends Mol Med"},{"issue":"1","key":"1929_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","volume":"7","author":"V Petrova","year":"2018","unstructured":"Petrova V, Annicchiarico-Petruzzelli M, Melino G, Amelio I. The hypoxic tumour microenvironment. Oncogenesis. 2018;7(1):10-017-0011-9. https:\/\/doi.org\/10.1038\/s41389-017-0011-9.","journal-title":"Oncogenesis"},{"issue":"1","key":"1929_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","volume":"12","author":"B Keith","year":"2011","unstructured":"Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011;12(1):9\u201322. https:\/\/doi.org\/10.1038\/nrc3183.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"1929_CR21","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3748\/wjg.v10.i8.1082","volume":"10","author":"YH Shi","year":"2004","unstructured":"Shi YH, Fang WG. Hypoxia-inducible factor-1 in tumour angiogenesis. World J Gastroenterol. 2004;10(8):1082\u20137. https:\/\/doi.org\/10.3748\/wjg.v10.i8.1082.","journal-title":"World J Gastroenterol"},{"issue":"25","key":"1929_CR22","doi-asserted-by":"publisher","first-page":"16767","DOI":"10.1074\/jbc.M901790200","volume":"284","author":"DR Mole","year":"2009","unstructured":"Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem. 2009;284(25):16767\u201375. https:\/\/doi.org\/10.1074\/jbc.M901790200.","journal-title":"J Biol Chem"},{"issue":"23","key":"1929_CR23","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1182\/blood-2010-10-314427","volume":"117","author":"J Schodel","year":"2011","unstructured":"Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood. 2011;117(23):e207\u201317. https:\/\/doi.org\/10.1182\/blood-2010-10-314427.","journal-title":"Blood"},{"key":"1929_CR24","doi-asserted-by":"publisher","unstructured":"Kuryk L, Bertinato L, Staniszewska M, Pancer K, Wieczorek M, Salmaso S, et al. From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. Cancers (Basel). 2020;12(10). https:\/\/doi.org\/10.3390\/cancers12103057.","DOI":"10.3390\/cancers12103057"},{"key":"1929_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3389\/fonc.2018.00173","volume":"8","author":"F Ahmed","year":"2018","unstructured":"Ahmed F, Haass NK. Microenvironment-driven dynamic heterogeneity and phenotypic plasticity as a mechanism of melanoma therapy resistance. Front Oncol. 2018;8:173. https:\/\/doi.org\/10.3389\/fonc.2018.00173.","journal-title":"Front Oncol"},{"key":"1929_CR26","doi-asserted-by":"publisher","unstructured":"Falcone I, Conciatori F, Bazzichetto C, Ferretti G, Cognetti F, Ciuffreda L, et al. Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. Cancers (Basel). 2020;12(10). https:\/\/doi.org\/10.3390\/cancers12102870.","DOI":"10.3390\/cancers12102870"},{"key":"1929_CR27","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3389\/fcell.2020.00662","volume":"8","author":"A Dumond","year":"2020","unstructured":"Dumond A, Pages G. Neuropilins, as relevant oncology target: their role in the Tumoral microenvironment. Front Cell Dev Biol. 2020;8:662. https:\/\/doi.org\/10.3389\/fcell.2020.00662.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"1929_CR28","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.7150\/thno.54023","volume":"11","author":"R Mastrantonio","year":"2021","unstructured":"Mastrantonio R, You H, Tamagnone L. Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer. Theranostics. 2021;11(7):3262\u201377. https:\/\/doi.org\/10.7150\/thno.54023.","journal-title":"Theranostics"},{"key":"1929_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-030-35582-1_3","volume":"1223","author":"S Niland","year":"2020","unstructured":"Niland S, Eble JA. Neuropilin: handyman and power broker in the tumor microenvironment. Adv Exp Med Biol. 2020;1223:31\u201367. https:\/\/doi.org\/10.1007\/978-3-030-35582-1_3.","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"1929_CR30","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.tibs.2008.01.006","volume":"33","author":"Y Zhou","year":"2008","unstructured":"Zhou Y, Gunput RA, Pasterkamp RJ. Semaphorin signaling: progress made and promises ahead. Trends Biochem Sci. 2008;33(4):161\u201370. https:\/\/doi.org\/10.1016\/j.tibs.2008.01.006.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"1929_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0092-8674(00)80063-X","volume":"99","author":"L Tamagnone","year":"1999","unstructured":"Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell. 1999;99(1):71\u201380. https:\/\/doi.org\/10.1016\/S0092-8674(00)80063-X.","journal-title":"Cell"},{"issue":"3","key":"1929_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.pbiomolbio.2015.03.006","volume":"118","author":"HG Pascoe","year":"2015","unstructured":"Pascoe HG, Wang Y, Zhang X. Structural mechanisms of plexin signaling. Prog Biophys Mol Biol. 2015;118(3):161\u20138. https:\/\/doi.org\/10.1016\/j.pbiomolbio.2015.03.006.","journal-title":"Prog Biophys Mol Biol"},{"issue":"49","key":"1929_CR33","doi-asserted-by":"publisher","first-page":"29120","DOI":"10.1074\/jbc.R115.687327","volume":"290","author":"HF Guo","year":"2015","unstructured":"Guo HF, Vander Kooi CW. Neuropilin functions as an essential cell surface receptor. J Biol Chem. 2015;290(49):29120\u20136. https:\/\/doi.org\/10.1074\/jbc.R115.687327.","journal-title":"J Biol Chem"},{"issue":"9","key":"1929_CR34","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1096\/fj.05-5646com","volume":"20","author":"T Karpanen","year":"2006","unstructured":"Karpanen T, Heckman CA, Keskitalo S, Jeltsch M, Ollila H, Neufeld G, et al. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB J. 2006;20(9):1462\u201372. https:\/\/doi.org\/10.1096\/fj.05-5646com.","journal-title":"FASEB J"},{"issue":"1","key":"1929_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1083\/jcb.200903137","volume":"188","author":"Y Xu","year":"2010","unstructured":"Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol. 2010;188(1):115\u201330. https:\/\/doi.org\/10.1083\/jcb.200903137.","journal-title":"J Cell Biol"},{"issue":"3","key":"1929_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.semcdb.2012.11.003","volume":"24","author":"C Siebold","year":"2013","unstructured":"Siebold C, Jones EY. Structural insights into semaphorins and their receptors. Semin Cell Dev Biol. 2013;24(3):139\u201345. https:\/\/doi.org\/10.1016\/j.semcdb.2012.11.003.","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"1929_CR37","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/pros.21281","volume":"71","author":"V Blanc","year":"2011","unstructured":"Blanc V, Nariculam J, Munson P, Freeman A, Klocker H, Masters J, et al. A role for class 3 semaphorins in prostate cancer. Prostate. 2011;71(6):649\u201358. https:\/\/doi.org\/10.1002\/pros.21281.","journal-title":"Prostate"},{"issue":"5","key":"1929_CR38","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1172\/JCI58976","volume":"122","author":"F Maione","year":"2012","unstructured":"Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest. 2012;122(5):1832\u201348. https:\/\/doi.org\/10.1172\/JCI58976.","journal-title":"J Clin Invest"},{"issue":"6","key":"1929_CR39","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ccr.2013.11.007","volume":"24","author":"A Casazza","year":"2013","unstructured":"Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A\/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell. 2013;24(6):695\u2013709. https:\/\/doi.org\/10.1016\/j.ccr.2013.11.007.","journal-title":"Cancer Cell"},{"issue":"1","key":"1929_CR40","doi-asserted-by":"publisher","DOI":"10.4161\/onci.27872","volume":"3","author":"A Casazza","year":"2014","unstructured":"Casazza A, Mazzone M. Altering the intratumoral localization of macrophages to inhibit cancer progression. Oncoimmunology. 2014;3(1):e27872. https:\/\/doi.org\/10.4161\/onci.27872.","journal-title":"Oncoimmunology"},{"key":"1929_CR41","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphys.2018.01662","volume":"9","author":"H Nakayama","year":"2018","unstructured":"Nakayama H, Kusumoto C, Nakahara M, Fujiwara A, Higashiyama S. Semaphorin 3F and Netrin-1: the novel function as a regulator of tumor microenvironment. Front Physiol. 2018;9:1662. https:\/\/doi.org\/10.3389\/fphys.2018.01662.","journal-title":"Front Physiol"},{"issue":"18","key":"1929_CR42","doi-asserted-by":"publisher","first-page":"8708","DOI":"10.1158\/0008-5472.CAN-06-3612","volume":"67","author":"VA Potiron","year":"2007","unstructured":"Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, et al. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res. 2007;67(18):8708\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-3612.","journal-title":"Cancer Res"},{"issue":"2","key":"1929_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1593\/neo.81074","volume":"11","author":"J Clarhaut","year":"2009","unstructured":"Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, et al. ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. Neoplasia. 2009;11(2):157\u201366. https:\/\/doi.org\/10.1593\/neo.81074.","journal-title":"Neoplasia"},{"issue":"3","key":"1929_CR44","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/0008-5472.CAN-03-3090","volume":"64","author":"O Kessler","year":"2004","unstructured":"Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L, et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res. 2004;64(3):1008\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-3090.","journal-title":"Cancer Res"},{"issue":"9","key":"1929_CR45","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1172\/JCI21378","volume":"114","author":"DR Bielenberg","year":"2004","unstructured":"Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest. 2004;114(9):1260\u201371. https:\/\/doi.org\/10.1172\/JCI21378.","journal-title":"J Clin Invest"},{"issue":"1","key":"1929_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/cr.2011.198","volume":"22","author":"A Sakurai","year":"2012","unstructured":"Sakurai A, Doci CL, Gutkind JS. Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer. Cell Res. 2012;22(1):23\u201332. https:\/\/doi.org\/10.1038\/cr.2011.198.","journal-title":"Cell Res"},{"issue":"12","key":"1929_CR47","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1248\/bpb.b18-00423","volume":"41","author":"X Liu","year":"2018","unstructured":"Liu X, Sun Y, Tian W, Wang F, Lv X, Wang M, et al. Sema4A responds to hypoxia and is involved in breast Cancer progression. Biol Pharm Bull. 2018;41(12):1791\u20136. https:\/\/doi.org\/10.1248\/bpb.b18-00423.","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"1929_CR48","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.cellsig.2015.02.027","volume":"27","author":"H Jian","year":"2015","unstructured":"Jian H, Zhao Y, Liu B, Lu S. SEMA4B inhibits growth of non-small cell lung cancer in vitro and in vivo. Cell Signal. 2015;27(6):1208\u201313. https:\/\/doi.org\/10.1016\/j.cellsig.2015.02.027.","journal-title":"Cell Signal"},{"issue":"11","key":"1929_CR49","doi-asserted-by":"publisher","first-page":"11051","DOI":"10.1007\/s13277-014-2409-8","volume":"35","author":"H Jian","year":"2014","unstructured":"Jian H, Zhao Y, Liu B, Lu S. SEMA4b inhibits MMP9 to prevent metastasis of non-small cell lung cancer. Tumour Biol. 2014;35(11):11051\u20136. https:\/\/doi.org\/10.1007\/s13277-014-2409-8.","journal-title":"Tumour Biol"},{"issue":"5","key":"1929_CR50","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1007\/s13277-014-1651-4","volume":"35","author":"H Jian","year":"2014","unstructured":"Jian H, Liu B, Zhang J. Hypoxia and hypoxia-inducible factor 1 repress SEMA4B expression to promote non-small cell lung cancer invasion. Tumour Biol. 2014;35(5):4949\u201355. https:\/\/doi.org\/10.1007\/s13277-014-1651-4.","journal-title":"Tumour Biol"},{"issue":"20","key":"1929_CR51","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.3760\/cma.j.issn.0366-6999.20141114","volume":"127","author":"L Mu","year":"2014","unstructured":"Mu L, Wang J, Chen Y, Li L, Guo X, Zheng S, et al. Hypoxia-inducible factor-1alpha and semaphorin4D genes involved with tumor-associated macrophage-induced metastatic behavior and clinical significance in colon cancer. Chin Med J. 2014;127(20):3568\u201375.","journal-title":"Chin Med J"},{"issue":"7","key":"1929_CR52","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.3748\/wjg.v21.i7.2191","volume":"21","author":"JS Wang","year":"2015","unstructured":"Wang JS, Jing CQ, Shan KS, Chen YZ, Guo XB, Cao ZX, et al. Semaphorin 4D and hypoxia-inducible factor-1alpha overexpression is related to prognosis in colorectal carcinoma. World J Gastroenterol. 2015;21(7):2191\u20138. https:\/\/doi.org\/10.3748\/wjg.v21.i7.2191.","journal-title":"World J Gastroenterol"},{"issue":"46","key":"1929_CR53","doi-asserted-by":"publisher","first-page":"32066","DOI":"10.1074\/jbc.M109.057166","volume":"284","author":"Q Sun","year":"2009","unstructured":"Sun Q, Zhou H, Binmadi NO, Basile JR. Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity. J Biol Chem. 2009;284(46):32066\u201374. https:\/\/doi.org\/10.1074\/jbc.M109.057166.","journal-title":"J Biol Chem"},{"issue":"14","key":"1929_CR54","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.yexcr.2012.04.019","volume":"318","author":"H Zhou","year":"2012","unstructured":"Zhou H, Yang YH, Binmadi NO, Proia P, Basile JR. The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma. Exp Cell Res. 2012;318(14):1685\u201398. https:\/\/doi.org\/10.1016\/j.yexcr.2012.04.019.","journal-title":"Exp Cell Res"},{"issue":"1","key":"1929_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10585-018-9951-5","volume":"36","author":"WG Chen","year":"2019","unstructured":"Chen WG, Sun J, Shen WW, Yang SZ, Zhang Y, Hu X, et al. Sema4D expression and secretion are increased by HIF-1alpha and inhibit osteogenesis in bone metastases of lung cancer. Clin Exp Metastasis. 2019;36(1):39\u201356. https:\/\/doi.org\/10.1007\/s10585-018-9951-5.","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"1929_CR56","doi-asserted-by":"publisher","first-page":"903","DOI":"10.7150\/jca.28169","volume":"10","author":"L Qiu","year":"2019","unstructured":"Qiu L, Jiang H, Luo J, Xi J, Wang X, Pan Y, et al. Regulatory sequence analysis of semaphorin 4D 5\u2032 non-coding region. J Cancer. 2019;10(4):903\u201310. https:\/\/doi.org\/10.7150\/jca.28169.","journal-title":"J Cancer"},{"issue":"10","key":"1929_CR57","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.addr.2009.04.017","volume":"61","author":"M Lee","year":"2009","unstructured":"Lee M. Hypoxia targeting gene expression for breast cancer gene therapy. Adv Drug Deliv Rev. 2009;61(10):842\u20139. https:\/\/doi.org\/10.1016\/j.addr.2009.04.017.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1929_CR58","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10555-007-9066-y","volume":"26","author":"D Liao","year":"2007","unstructured":"Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007;26(2):281\u201390. https:\/\/doi.org\/10.1007\/s10555-007-9066-y.","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"1929_CR59","doi-asserted-by":"publisher","first-page":"13264","DOI":"10.3390\/ijms131013264","volume":"13","author":"Y Chen","year":"2012","unstructured":"Chen Y, Zhang L, Pan Y, Ren X, Hao Q. Over-expression of semaphorin4D, hypoxia-inducible factor-1alpha and vascular endothelial growth factor is related to poor prognosis in ovarian epithelial cancer. Int J Mol Sci. 2012;13(10):13264\u201374. https:\/\/doi.org\/10.3390\/ijms131013264.","journal-title":"Int J Mol Sci"},{"key":"1929_CR60","first-page":"341","volume":"10","author":"P Ottino","year":"2004","unstructured":"Ottino P, Finley J, Rojo E, Ottlecz A, Lambrou GN, Bazan HE, et al. Hypoxia activates matrix metalloproteinase expression and the VEGF system in monkey choroid-retinal endothelial cells: involvement of cytosolic phospholipase A2 activity. Mol Vis. 2004;10:341\u201350.","journal-title":"Mol Vis"},{"issue":"5","key":"1929_CR61","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1074\/jbc.M406613200","volume":"280","author":"K Brusselmans","year":"2005","unstructured":"Brusselmans K, Bono F, Collen D, Herbert JM, Carmeliet P, Dewerchin M. A novel role for vascular endothelial growth factor as an autocrine survival factor for embryonic stem cells during hypoxia. J Biol Chem. 2005;280(5):3493\u20139. https:\/\/doi.org\/10.1074\/jbc.M406613200.","journal-title":"J Biol Chem"},{"issue":"8","key":"1929_CR62","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1093\/nar\/gkv1471","volume":"44","author":"A de Bruin","year":"2016","unstructured":"de Bruin A, PW AC, Kirchmaier BC, Mokry M, Iich E, Nirmala E, et al. Genome-wide analysis reveals NRP1 as a direct HIF1alpha-E2F7 target in the regulation of motorneuron guidance in vivo. Nucleic Acids Res. 2016;44(8):3549\u201366.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"1929_CR63","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/1097-0215(20001115)88:4<584::AID-IJC11>3.0.CO;2-T","volume":"88","author":"H Ding","year":"2000","unstructured":"Ding H, Wu X, Roncari L, Lau N, Shannon P, Nagy A, et al. Expression and regulation of neuropilin-1 in human astrocytomas. Int J Cancer. 2000;88(4):584\u201392. https:\/\/doi.org\/10.1002\/1097-0215(20001115)88:4<584::AID-IJC11>3.0.CO;2-T.","journal-title":"Int J Cancer"},{"issue":"2","key":"1929_CR64","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.yexcr.2004.01.013","volume":"295","author":"A Jogi","year":"2004","unstructured":"Jogi A, Vallon-Christersson J, Holmquist L, Axelson H, Borg A, Pahlman S. Human neuroblastoma cells exposed to hypoxia: induction of genes associated with growth, survival, and aggressive behavior. Exp Cell Res. 2004;295(2):469\u201387. https:\/\/doi.org\/10.1016\/j.yexcr.2004.01.013.","journal-title":"Exp Cell Res"},{"issue":"4","key":"1929_CR65","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2174\/1566524016666160316153623","volume":"16","author":"S Shi","year":"2016","unstructured":"Shi S, Xu J, Zhang B, Ji S, Xu W, Liu J, et al. VEGF promotes glycolysis in pancreatic Cancer via HIF1alpha up-regulation. Curr Mol Med. 2016;16(4):394\u2013403. https:\/\/doi.org\/10.2174\/1566524016666160316153623.","journal-title":"Curr Mol Med"},{"issue":"1","key":"1929_CR66","first-page":"41","volume":"32","author":"MP Barr","year":"2008","unstructured":"Barr MP, Bouchier-Hayes DJ, Harmey JJ. Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. Int J Oncol. 2008;32(1):41\u20138.","journal-title":"Int J Oncol"},{"issue":"12","key":"1929_CR67","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.2217\/14622416.8.12.1705","volume":"8","author":"M Azuma","year":"2007","unstructured":"Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, et al. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics. 2007;8(12):1705\u201313. https:\/\/doi.org\/10.2217\/14622416.8.12.1705.","journal-title":"Pharmacogenomics"},{"issue":"11","key":"1929_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050153","volume":"7","author":"RM Misra","year":"2012","unstructured":"Misra RM, Bajaj MS, Kale VP. Vasculogenic mimicry of HT1080 tumour cells in vivo: critical role of HIF-1alpha-neuropilin-1 axis. PLoS One. 2012;7(11):e50153. https:\/\/doi.org\/10.1371\/journal.pone.0050153.","journal-title":"PLoS One"},{"issue":"3","key":"1929_CR69","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/mc.22936","volume":"58","author":"XJ Chen","year":"2019","unstructured":"Chen XJ, Wu S, Yan RM, Fan LS, Yu L, Zhang YM, et al. The role of the hypoxia-Nrp-1 axis in the activation of M2-like tumor-associated macrophages in the tumor microenvironment of cervical cancer. Mol Carcinog. 2019;58(3):388\u201397. https:\/\/doi.org\/10.1002\/mc.22936.","journal-title":"Mol Carcinog"},{"issue":"22","key":"1929_CR70","doi-asserted-by":"publisher","first-page":"11121","DOI":"10.18632\/oncotarget.2553","volume":"5","author":"PY Zhuang","year":"2014","unstructured":"Zhuang PY, Wang JD, Tang ZH, Zhou XP, Yang Y, Quan ZW, et al. Peritumoral Neuropilin-1 and VEGF receptor-2 expression increases time to recurrence in hepatocellular carcinoma patients undergoing curative hepatectomy. Oncotarget. 2014;5(22):11121\u201332. https:\/\/doi.org\/10.18632\/oncotarget.2553.","journal-title":"Oncotarget"},{"issue":"2","key":"1929_CR71","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.leukres.2011.08.017","volume":"36","author":"S Younan","year":"2012","unstructured":"Younan S, Elhoseiny S, Hammam A, Gawdat R, El-Wakil M, Fawzy M. Role of neuropilin-1 and its expression in Egyptian acute myeloid and acute lymphoid leukemia patients. Leuk Res. 2012;36(2):169\u201373. https:\/\/doi.org\/10.1016\/j.leukres.2011.08.017.","journal-title":"Leuk Res"},{"issue":"6","key":"1929_CR72","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.1007\/s13277-014-1806-3","volume":"35","author":"W Cheng","year":"2014","unstructured":"Cheng W, Fu D, Wei ZF, Xu F, Xu XF, Liu YH, et al. NRP-1 expression in bladder cancer and its implications for tumor progression. Tumour Biol. 2014;35(6):6089\u201394. https:\/\/doi.org\/10.1007\/s13277-014-1806-3.","journal-title":"Tumour Biol"},{"issue":"5","key":"1929_CR73","first-page":"2065","volume":"33","author":"M Talagas","year":"2013","unstructured":"Talagas M, Uguen A, Garlantezec R, Fournier G, Doucet L, Gobin E, et al. VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer. Anticancer Res. 2013;33(5):2065\u201375.","journal-title":"Anticancer Res"},{"issue":"9","key":"1929_CR74","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1158\/0008-5472.CAN-04-2229","volume":"65","author":"MJ Gray","year":"2005","unstructured":"Gray MJ, Wey JS, Belcheva A, McCarty MF, Trevino JG, Evans DB, et al. Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res. 2005;65(9):3664\u201370. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-2229.","journal-title":"Cancer Res"},{"issue":"16","key":"1929_CR75","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1158\/1078-0432.CCR-07-0001","volume":"13","author":"TM Hong","year":"2007","unstructured":"Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC, et al. Targeting neuropilin 1 as an antitumor strategy in lung cancer. Clin Cancer Res. 2007;13(16):4759\u201368. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0001.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1929_CR76","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2006.10.018","volume":"11","author":"Q Pan","year":"2007","unstructured":"Pan Q, Chanthery Y, Liang WC, Stawicki S, Mak J, Rathore N, et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell. 2007;11(1):53\u201367. https:\/\/doi.org\/10.1016\/j.ccr.2006.10.018.","journal-title":"Cancer Cell"},{"issue":"2","key":"1929_CR77","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1042\/BJ20071639","volume":"411","author":"C Pellet-Many","year":"2008","unstructured":"Pellet-Many C, Frankel P, Jia H, Zachary I. Neuropilins: structure, function and role in disease. Biochem J. 2008;411(2):211\u201326. https:\/\/doi.org\/10.1042\/BJ20071639.","journal-title":"Biochem J"},{"issue":"15","key":"1929_CR78","first-page":"5736","volume":"61","author":"RE Bachelder","year":"2001","unstructured":"Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001;61(15):5736\u201340.","journal-title":"Cancer Res"},{"key":"1929_CR79","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3389\/fonc.2020.01612","volume":"10","author":"Y Jin","year":"2020","unstructured":"Jin Y, Che X, Qu X, Li X, Lu W, Wu J, et al. CircHIPK3 promotes metastasis of gastric Cancer via miR-653-5p\/miR-338-3p-NRP1 Axis under a long-term hypoxic microenvironment. Front Oncol. 2020;10:1612. https:\/\/doi.org\/10.3389\/fonc.2020.01612.","journal-title":"Front Oncol"},{"issue":"3","key":"1929_CR80","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4161\/cam.5.3.16294","volume":"5","author":"S Coma","year":"2011","unstructured":"Coma S, Shimizu A, Klagsbrun M. Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2. Cell Adhes Migr. 2011;5(3):266\u201375. https:\/\/doi.org\/10.4161\/cam.5.3.16294.","journal-title":"Cell Adhes Migr"},{"issue":"11","key":"1929_CR81","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.2174\/138920112802502088","volume":"13","author":"E Raskopf","year":"2012","unstructured":"Raskopf E, Vogt A, Decker G, Hirt S, Daskalow K, Cramer T, et al. Combination of hypoxia and RNA-interference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms. Curr Pharm Biotechnol. 2012;13(11):2290\u20138. https:\/\/doi.org\/10.2174\/138920112802502088.","journal-title":"Curr Pharm Biotechnol"},{"issue":"2","key":"1929_CR82","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/jnci\/djm279","volume":"100","author":"MJ Gray","year":"2008","unstructured":"Gray MJ, Van Buren G, Dallas NA, Xia L, Wang X, Yang AD, et al. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 2008;100(2):109\u201320. https:\/\/doi.org\/10.1093\/jnci\/djm279.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1929_CR83","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/jid.2008.329","volume":"129","author":"GA Scott","year":"2009","unstructured":"Scott GA, McClelland LA, Fricke AF, Fender A. Plexin C1, a receptor for semaphorin 7a, inactivates cofilin and is a potential tumor suppressor for melanoma progression. J Invest Dermatol. 2009;129(4):954\u201363. https:\/\/doi.org\/10.1038\/jid.2008.329.","journal-title":"J Invest Dermatol"},{"issue":"15","key":"1929_CR84","doi-asserted-by":"publisher","first-page":"6164","DOI":"10.1073\/pnas.0811521106","volume":"106","author":"Q Schwarz","year":"2009","unstructured":"Schwarz Q, Maden CH, Vieira JM, Ruhrberg C. Neuropilin 1 signaling guides neural crest cells to coordinate pathway choice with cell specification. Proc Natl Acad Sci U S A. 2009;106(15):6164\u20139. https:\/\/doi.org\/10.1073\/pnas.0811521106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1929_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033633","volume":"7","author":"G Chakraborty","year":"2012","unstructured":"Chakraborty G, Kumar S, Mishra R, Patil TV, Kundu GC. Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model. PLoS One. 2012;7(3):e33633. https:\/\/doi.org\/10.1371\/journal.pone.0033633.","journal-title":"PLoS One"},{"issue":"5","key":"1929_CR86","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/CMR.0000000000000674","volume":"30","author":"G Lucarini","year":"2020","unstructured":"Lucarini G, Simonetti O, Lazzarini R, Giantomassi F, Goteri G, Offidani A. Vascular endothelial growth factor\/semaphorin-3A ratio and SEMA3A expression in cutaneous malignant melanoma. Melanoma Res. 2020;30(5):433\u201342. https:\/\/doi.org\/10.1097\/CMR.0000000000000674.","journal-title":"Melanoma Res"},{"issue":"6","key":"1929_CR87","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s004030100232","volume":"293","author":"A Gutgemann","year":"2001","unstructured":"Gutgemann A, Golob M, Muller S, Buettner R, Bosserhoff AK. Isolation of invasion-associated cDNAs in melanoma. Arch Dermatol Res. 2001;293(6):283\u201390. https:\/\/doi.org\/10.1007\/s004030100232.","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"1929_CR88","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2353\/ajpath.2008.080136","volume":"173","author":"I Roodink","year":"2008","unstructured":"Roodink I, Kats G, van Kempen L, Grunberg M, Maass C, Verrijp K, et al. Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression. Am J Pathol. 2008;173(6):1873\u201381. https:\/\/doi.org\/10.2353\/ajpath.2008.080136.","journal-title":"Am J Pathol"},{"issue":"6","key":"1929_CR89","first-page":"1238","volume":"58","author":"CR Christensen","year":"1998","unstructured":"Christensen CR, Klingelhofer J, Tarabykina S, Hulgaard EF, Kramerov D, Lukanidin E. Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines. Cancer Res. 1998;58(6):1238\u201344.","journal-title":"Cancer Res"},{"issue":"8","key":"1929_CR90","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1172\/JCI42118","volume":"120","author":"A Casazza","year":"2010","unstructured":"Casazza A, Finisguerra V, Capparuccia L, Camperi A, Swiercz JM, Rizzolio S, et al. Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. J Clin Invest. 2010;120(8):2684\u201398. https:\/\/doi.org\/10.1172\/JCI42118.","journal-title":"J Clin Invest"},{"issue":"8","key":"1929_CR91","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1172\/JCI44110","volume":"120","author":"M Klagsbrun","year":"2010","unstructured":"Klagsbrun M, Shimizu A. Semaphorin 3E, an exception to the rule. J Clin Invest. 2010;120(8):2658\u201360. https:\/\/doi.org\/10.1172\/JCI44110.","journal-title":"J Clin Invest"},{"key":"1929_CR92","doi-asserted-by":"publisher","unstructured":"York JR, Yuan T, Lakiza O, McCauley DW. An ancestral role for Semaphorin3F-Neuropilin signaling in patterning neural crest within the new vertebrate head. Development. 2018;145(14). https:\/\/doi.org\/10.1242\/dev.164780.","DOI":"10.1242\/dev.164780"},{"issue":"10","key":"1929_CR93","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/sj.jid.5700382","volume":"126","author":"I Chabbert-de Ponnat","year":"2006","unstructured":"Chabbert-de Ponnat I, Buffard V, Leroy K, Bagot M, Bensussan A, Wolkenstein P, et al. Antiproliferative effect of semaphorin 3F on human melanoma cell lines. J Invest Dermatol. 2006;126(10):2343\u20135. https:\/\/doi.org\/10.1038\/sj.jid.5700382.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"1929_CR94","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1158\/0008-5472.CAN-09-3048","volume":"70","author":"S Coma","year":"2010","unstructured":"Coma S, Amin DN, Shimizu A, Lasorella A, Iavarone A, Klagsbrun M. Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. Cancer Res. 2010;70(9):3823\u201332. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3048.","journal-title":"Cancer Res"},{"issue":"4","key":"1929_CR95","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/jid.2011.414","volume":"132","author":"J Soong","year":"2012","unstructured":"Soong J, Chen Y, Shustef EM, Scott GA. Sema4D, the ligand for Plexin B1, suppresses c-met activation and migration and promotes melanocyte survival and growth. J Invest Dermatol. 2012;132(4):1230\u20138. https:\/\/doi.org\/10.1038\/jid.2011.414.","journal-title":"J Invest Dermatol"},{"issue":"Pt 2","key":"1929_CR96","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1242\/jcs.119487","volume":"126","author":"J Soong","year":"2013","unstructured":"Soong J, Scott G. Plexin B1 inhibits MET through direct association and regulates Shp2 expression in melanocytes. J Cell Sci. 2013;126(Pt 2):688\u201395. https:\/\/doi.org\/10.1242\/jcs.119487.","journal-title":"J Cell Sci"},{"issue":"7","key":"1929_CR97","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1038\/jid.2010.45","volume":"130","author":"S Damm","year":"2010","unstructured":"Damm S, Koefinger P, Stefan M, Wels C, Mehes G, Richtig E, et al. HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C\/EBP-beta. J Invest Dermatol. 2010;130(7):1893\u2013903. https:\/\/doi.org\/10.1038\/jid.2010.45.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1929_CR98","doi-asserted-by":"publisher","first-page":"E56","DOI":"10.1002\/ijc.26487","volume":"131","author":"C Chattopadhyay","year":"2012","unstructured":"Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA. Association of activated c-met with NRAS-mutated human melanomas. Int J Cancer. 2012;131(2):E56\u201365. https:\/\/doi.org\/10.1002\/ijc.26487.","journal-title":"Int J Cancer"},{"issue":"1","key":"1929_CR99","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1566523220666200516170832","volume":"20","author":"S Chen","year":"2020","unstructured":"Chen S, Liu Z, Li M, Huang Y, Wang M, Zeng W, et al. Potential prognostic predictors and molecular targets for skin melanoma screened by weighted gene co-expression network analysis. Curr Gene Ther. 2020;20(1):5\u201314. https:\/\/doi.org\/10.2174\/1566523220666200516170832.","journal-title":"Curr Gene Ther"},{"issue":"22","key":"1929_CR100","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.3748\/wjg.15.2800","volume":"15","author":"GQ Pan","year":"2009","unstructured":"Pan GQ, Ren HZ, Zhang SF, Wang XM, Wen JF. Expression of semaphorin 5A and its receptor plexin B3 contributes to invasion and metastasis of gastric carcinoma. World J Gastroenterol. 2009;15(22):2800\u20134. https:\/\/doi.org\/10.3748\/wjg.15.2800.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"1929_CR101","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/ijc.25166","volume":"127","author":"A Sadanandam","year":"2010","unstructured":"Sadanandam A, Varney ML, Singh S, Ashour AE, Moniaux N, Deb S, et al. High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis. Int J Cancer. 2010;127(6):1373\u201383. https:\/\/doi.org\/10.1002\/ijc.25166.","journal-title":"Int J Cancer"},{"issue":"1","key":"1929_CR102","first-page":"278\u2013018-0933-x","volume":"37","author":"S D'Aguanno","year":"2018","unstructured":"D'Aguanno S, Valentini E, Tupone MG, Desideri M, Di Martile M, Spagnuolo M, et al. Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. J Exp Clin Cancer Res. 2018;37(1):278\u2013018-0933-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"19","key":"1929_CR103","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/0008-5472.CAN-19-0054","volume":"79","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Pusch S, Innes J, Sidlauskas K, Ellis M, Lau J, et al. Mutant IDH sensitizes Gliomas to endoplasmic reticulum stress and triggers apoptosis via miR-183-mediated inhibition of Semaphorin 3E. Cancer Res. 2019;79(19):4994\u20135007. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0054.","journal-title":"Cancer Res"},{"issue":"5\u20136","key":"1929_CR104","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/iep.12342","volume":"100","author":"MB Aksenenko","year":"2019","unstructured":"Aksenenko MB, Palkina NV, Sergeeva ON, Yu Sergeeva E, Kirichenko AK, Ruksha TG. miR-155 overexpression is followed by downregulation of its target gene, NFE2L2, and altered pattern of VEGFA expression in the liver of melanoma B16-bearing mice at the premetastatic stage. Int J Exp Pathol. 2019;100(5\u20136):311\u20139. https:\/\/doi.org\/10.1111\/iep.12342.","journal-title":"Int J Exp Pathol"},{"issue":"5","key":"1929_CR105","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.18632\/oncotarget.2995","volume":"6","author":"R Loria","year":"2015","unstructured":"Loria R, Bon G, Perotti V, Gallo E, Bersani I, Baldassari P, et al. Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells. Oncotarget. 2015;6(5):2779\u201393. https:\/\/doi.org\/10.18632\/oncotarget.2995.","journal-title":"Oncotarget"},{"issue":"1","key":"1929_CR106","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/sj.jid.5700974","volume":"128","author":"GA Scott","year":"2008","unstructured":"Scott GA, McClelland LA, Fricke AF. Semaphorin 7a promotes spreading and dendricity in human melanocytes through beta1-integrins. J Invest Dermatol. 2008;128(1):151\u201361. https:\/\/doi.org\/10.1038\/sj.jid.5700974.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1929_CR107","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/0008-5472.CAN-13-3339","volume":"75","author":"B Ma","year":"2015","unstructured":"Ma B, Herzog EL, Lee CG, Peng X, Lee CM, Chen X, et al. Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. Cancer Res. 2015;75(3):487\u201396. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-3339.","journal-title":"Cancer Res"},{"key":"1929_CR108","doi-asserted-by":"publisher","first-page":"24\u20138104-9-24","DOI":"10.1186\/1749-8104-9-24","volume":"9","author":"R Lumb","year":"2014","unstructured":"Lumb R, Wiszniak S, Kabbara S, Scherer M, Harvey N, Schwarz Q. Neuropilins define distinct populations of neural crest cells. Neural Dev. 2014;9:24\u20138104-9-24.","journal-title":"Neural Dev"},{"issue":"7457","key":"1929_CR109","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214\u20138. https:\/\/doi.org\/10.1038\/nature12213.","journal-title":"Nature"},{"issue":"11","key":"1929_CR110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142819","volume":"10","author":"M Pyatnitskiy","year":"2015","unstructured":"Pyatnitskiy M, Karpov D, Poverennaya E, Lisitsa A, Moshkovskii S. Bringing down Cancer aircraft: searching for essential Hypomutated proteins in skin melanoma. PLoS One. 2015;10(11):e0142819. https:\/\/doi.org\/10.1371\/journal.pone.0142819.","journal-title":"PLoS One"},{"issue":"1","key":"1929_CR111","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1046\/j.1523-1747.2000.00022.x","volume":"115","author":"U Graeven","year":"2000","unstructured":"Graeven U, Rodeck U, Karpinski S, Jost M, Andre N, Schmiegel W. Expression patterns of placenta growth factor in human melanocytic cell lines. J Invest Dermatol. 2000;115(1):118\u201323. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00022.x.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"1929_CR112","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.0906-6705.2005.00345.x","volume":"14","author":"EJ Kim","year":"2005","unstructured":"Kim EJ, Park HY, Yaar M, Gilchrest BA. Modulation of vascular endothelial growth factor receptors in melanocytes. Exp Dermatol. 2005;14(8):625\u201333. https:\/\/doi.org\/10.1111\/j.0906-6705.2005.00345.x.","journal-title":"Exp Dermatol"},{"issue":"2","key":"1929_CR113","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.3892\/mmr.2015.3752","volume":"12","author":"J Lu","year":"2015","unstructured":"Lu J, Cheng Y, Zhang G, Tang Y, Dong Z, McElwee KJ, et al. Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma. Mol Med Rep. 2015;12(2):2668\u201376. https:\/\/doi.org\/10.3892\/mmr.2015.3752.","journal-title":"Mol Med Rep"},{"issue":"6","key":"1929_CR114","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","volume":"92","author":"S Soker","year":"1998","unstructured":"Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92(6):735\u201345. https:\/\/doi.org\/10.1016\/S0092-8674(00)81402-6.","journal-title":"Cell"},{"issue":"6","key":"1929_CR115","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1046\/j.1523-1747.2000.00199.x","volume":"115","author":"PM Lacal","year":"2000","unstructured":"Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol. 2000;115(6):1000\u20137. https:\/\/doi.org\/10.1046\/j.1523-1747.2000.00199.x.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1929_CR116","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.yexcr.2005.11.024","volume":"312","author":"DR Bielenberg","year":"2006","unstructured":"Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilins in neoplasms: expression, regulation, and function. Exp Cell Res. 2006;312(5):584\u201393. https:\/\/doi.org\/10.1016\/j.yexcr.2005.11.024.","journal-title":"Exp Cell Res"},{"issue":"9","key":"1929_CR117","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1172\/JCI99257","volume":"128","author":"S Rizzolio","year":"2018","unstructured":"Rizzolio S, Cagnoni G, Battistini C, Bonelli S, Isella C, Van Ginderachter JA, et al. Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies. J Clin Invest. 2018;128(9):3976\u201390. https:\/\/doi.org\/10.1172\/JCI99257.","journal-title":"J Clin Invest"},{"key":"1929_CR118","first-page":"16\u2013016\u20130291-5","volume":"35","author":"L Li","year":"2016","unstructured":"Li L, Jiang X, Zhang Q, Dong X, Gao Y, He Y, et al. Neuropilin-1 is associated with clinicopathology of gastric cancer and contributes to cell proliferation and migration as multifunctional co-receptors. J Exp Clin Cancer Res. 2016;35:16\u2013016\u20130291-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"1929_CR119","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fonc.2015.00125","volume":"5","author":"G Graziani","year":"2015","unstructured":"Graziani G, Lacal PM. Neuropilin-1 as therapeutic target for malignant melanoma. Front Oncol. 2015;5:125.","journal-title":"Front Oncol"},{"issue":"6","key":"1929_CR120","doi-asserted-by":"publisher","first-page":"E545","DOI":"10.1002\/ijc.29252","volume":"136","author":"F Ruffini","year":"2015","unstructured":"Ruffini F, Graziani G, Levati L, Tentori L, D'Atri S, Lacal PM. Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of alphavbeta5 integrin. Int J Cancer. 2015;136(6):E545\u201358. https:\/\/doi.org\/10.1002\/ijc.29252.","journal-title":"Int J Cancer"},{"issue":"1","key":"1929_CR121","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3892\/ijo.2013.1948","volume":"43","author":"F Ruffini","year":"2013","unstructured":"Ruffini F, D'Atri S, Lacal PM. Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and -independent mechanisms. Int J Oncol. 2013;43(1):297\u2013306. https:\/\/doi.org\/10.3892\/ijo.2013.1948.","journal-title":"Int J Oncol"},{"issue":"4","key":"1929_CR122","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3892\/ijo.2016.3362","volume":"48","author":"E Pagani","year":"2016","unstructured":"Pagani E, Ruffini F, Antonini Cappellini GC, Scoppola A, Fortes C, Marchetti P, et al. Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness. Int J Oncol. 2016;48(4):1581\u20139. https:\/\/doi.org\/10.3892\/ijo.2016.3362.","journal-title":"Int J Oncol"},{"issue":"11","key":"1929_CR123","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1084\/jem.20111497","volume":"209","author":"W Hansen","year":"2012","unstructured":"Hansen W, Hutzler M, Abel S, Alter C, Stockmann C, Kliche S, et al. Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med. 2012;209(11):2001\u201316. https:\/\/doi.org\/10.1084\/jem.20111497.","journal-title":"J Exp Med"},{"issue":"1","key":"1929_CR124","doi-asserted-by":"publisher","first-page":"3345\u2013019-11280-","DOI":"10.1038\/s41467-019-11280-z","volume":"10","author":"M Leclerc","year":"2019","unstructured":"Leclerc M, Voilin E, Gros G, Corgnac S, de Montpreville V, Validire P, et al. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019;10(1):3345\u2013019-11280-z.","journal-title":"Nat Commun"},{"issue":"1","key":"1929_CR125","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4149\/neo_2012_006","volume":"59","author":"AM Mazurek","year":"2012","unstructured":"Mazurek AM, Olbryt M. The influence of neuropilin-1 silencing on semaphorin 3A and 3C activity in B16(F10) murine melanoma cells. Neoplasma. 2012;59(1):43\u201351. https:\/\/doi.org\/10.4149\/neo_2012_006.","journal-title":"Neoplasma"},{"issue":"3","key":"1929_CR126","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.humpath.2011.05.008","volume":"43","author":"EC Rushing","year":"2012","unstructured":"Rushing EC, Stine MJ, Hahn SJ, Shea S, Eller MS, Naif A, et al. Neuropilin-2: a novel biomarker for malignant melanoma? Hum Pathol. 2012;43(3):381\u20139. https:\/\/doi.org\/10.1016\/j.humpath.2011.05.008.","journal-title":"Hum Pathol"},{"issue":"1","key":"1929_CR127","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12967-017-1307-4","volume":"15","author":"R Huang","year":"2017","unstructured":"Huang R, Andersen LMK, Rofstad EK. Metastatic pathway and the microvascular and physicochemical microenvironments of human melanoma xenografts. J Transl Med. 2017;15(1):203-017-1307-4. https:\/\/doi.org\/10.1186\/s12967-017-1307-4.","journal-title":"J Transl Med"},{"issue":"2","key":"1929_CR128","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/bjd.12801","volume":"171","author":"M Rossi","year":"2014","unstructured":"Rossi M, Tuck J, Kim OJ, Panova I, Symanowski JT, Mahalingam M, et al. Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma. Br J Dermatol. 2014;171(2):403\u20138. https:\/\/doi.org\/10.1111\/bjd.12801.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1929_CR129","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/CMR.0000000000000190","volume":"26","author":"WF Moriarty","year":"2016","unstructured":"Moriarty WF, Kim E, Gerber SA, Hammers H, Alani RM. Neuropilin-2 promotes melanoma growth and progression in vivo. Melanoma Res. 2016;26(4):321\u20138. https:\/\/doi.org\/10.1097\/CMR.0000000000000190.","journal-title":"Melanoma Res"},{"issue":"7","key":"1929_CR130","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1158\/0008-5472.CAN-10-1875","volume":"71","author":"MJ Stine","year":"2011","unstructured":"Stine MJ, Wang CJ, Moriarty WF, Ryu B, Cheong R, Westra WH, et al. Integration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction. Cancer Res. 2011;71(7):2433\u201344. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1875.","journal-title":"Cancer Res"},{"issue":"2","key":"1929_CR131","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/geno.2000.6381","volume":"70","author":"M Rossignol","year":"2000","unstructured":"Rossignol M, Gagnon ML, Klagsbrun M. Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms. Genomics. 2000;70(2):211\u201322. https:\/\/doi.org\/10.1006\/geno.2000.6381.","journal-title":"Genomics"},{"issue":"8","key":"1929_CR132","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/1541-7786.MCR-10-0157","volume":"8","author":"E Geretti","year":"2010","unstructured":"Geretti E, van Meeteren LA, Shimizu A, Dudley AC, Claesson-Welsh L, Klagsbrun M. A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression. Mol Cancer Res. 2010;8(8):1063\u201373. https:\/\/doi.org\/10.1158\/1541-7786.MCR-10-0157.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1929_CR133","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jaad.2012.07.009","volume":"68","author":"J Wititsuwannakul","year":"2013","unstructured":"Wititsuwannakul J, Mason AR, Klump VR, Lazova R. Neuropilin-2 as a useful marker in the differentiation between Spitzoid malignant melanoma and Spitz nevus. J Am Acad Dermatol. 2013;68(1):129\u201337. https:\/\/doi.org\/10.1016\/j.jaad.2012.07.009.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1929_CR134","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/humu.21017","volume":"30","author":"A Balakrishnan","year":"2009","unstructured":"Balakrishnan A, Penachioni JY, Lamba S, Bleeker FE, Zanon C, Rodolfo M, et al. Molecular profiling of the \"plexinome\" in melanoma and pancreatic cancer. Hum Mutat. 2009;30(8):1167\u201374. https:\/\/doi.org\/10.1002\/humu.21017.","journal-title":"Hum Mutat"},{"issue":"4","key":"1929_CR135","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/1078-0432.CCR-06-2433","volume":"13","author":"A Rody","year":"2007","unstructured":"Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G, et al. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res. 2007;13(4):1115\u201322. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2433.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1929_CR136","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.trsl.2007.12.003","volume":"151","author":"JJ Gomez Roman","year":"2008","unstructured":"Gomez Roman JJ, Garay GO, Saenz P, Escuredo K, Sanz Ibayondo C, Gutkind S, et al. Plexin B1 is downregulated in renal cell carcinomas and modulates cell growth. Transl Res. 2008;151(3):134\u201340. https:\/\/doi.org\/10.1016\/j.trsl.2007.12.003.","journal-title":"Transl Res"},{"issue":"30","key":"1929_CR137","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1038\/sj.onc.1207650","volume":"23","author":"P Conrotto","year":"2004","unstructured":"Conrotto P, Corso S, Gamberini S, Comoglio PM, Giordano S. Interplay between scatter factor receptors and B plexins controls invasive growth. Oncogene. 2004;23(30):5131\u20137. https:\/\/doi.org\/10.1038\/sj.onc.1207650.","journal-title":"Oncogene"},{"issue":"6","key":"1929_CR138","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/jid.2010.13","volume":"130","author":"L Stevens","year":"2010","unstructured":"Stevens L, McClelland L, Fricke A, Williamson M, Kuo I, Scott G. Plexin B1 suppresses c-met in melanoma: a role for plexin B1 as a tumor-suppressor protein through regulation of c-met. J Invest Dermatol. 2010;130(6):1636\u201345. https:\/\/doi.org\/10.1038\/jid.2010.13.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"1929_CR139","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1755-148X.2010.00797.x","volume":"24","author":"L McClelland","year":"2011","unstructured":"McClelland L, Chen Y, Soong J, Kuo I, Scott G. Plexin B1 inhibits integrin-dependent pp125FAK and rho activity in melanoma. Pigment Cell Melanoma Res. 2011;24(1):165\u201374. https:\/\/doi.org\/10.1111\/j.1755-148X.2010.00797.x.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"30","key":"1929_CR140","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1038\/onc.2009.133","volume":"28","author":"GM Argast","year":"2009","unstructured":"Argast GM, Croy CH, Couts KL, Zhang Z, Litman E, Chan DC, et al. Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene. 2009;28(30):2697\u2013709. https:\/\/doi.org\/10.1038\/onc.2009.133.","journal-title":"Oncogene"},{"issue":"41","key":"1929_CR141","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1038\/onc.2012.511","volume":"32","author":"Y Chen","year":"2013","unstructured":"Chen Y, Soong J, Mohanty S, Xu L, Scott G. The neural guidance receptor Plexin C1 delays melanoma progression. Oncogene. 2013;32(41):4941\u20139. https:\/\/doi.org\/10.1038\/onc.2012.511.","journal-title":"Oncogene"},{"issue":"2","key":"1929_CR142","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/DAD.0b013e318196672d","volume":"31","author":"R Lazova","year":"2009","unstructured":"Lazova R, Gould Rothberg BE, Rimm D, Scott G. The semaphorin 7A receptor Plexin C1 is lost during melanoma metastasis. Am J Dermatopathol. 2009;31(2):177\u201381. https:\/\/doi.org\/10.1097\/DAD.0b013e318196672d.","journal-title":"Am J Dermatopathol"},{"issue":"25","key":"1929_CR143","doi-asserted-by":"publisher","first-page":"41749","DOI":"10.18632\/oncotarget.16978","volume":"8","author":"C Prunier","year":"2017","unstructured":"Prunier C, Prudent R, Kapur R, Sadoul K, Lafanechere L. LIM kinases: cofilin and beyond. Oncotarget. 2017;8(25):41749\u201363. https:\/\/doi.org\/10.18632\/oncotarget.16978.","journal-title":"Oncotarget"},{"issue":"2","key":"1929_CR144","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1091\/mbc.e04-07-0555","volume":"16","author":"P Hotulainen","year":"2005","unstructured":"Hotulainen P, Paunola E, Vartiainen MK, Lappalainen P. Actin-depolymerizing factor and cofilin-1 play overlapping roles in promoting rapid F-actin depolymerization in mammalian nonmuscle cells. Mol Biol Cell. 2005;16(2):649\u201364. https:\/\/doi.org\/10.1091\/mbc.e04-07-0555.","journal-title":"Mol Biol Cell"},{"issue":"3","key":"1929_CR145","first-page":"1117","volume":"5","author":"MY Kumasaka","year":"2015","unstructured":"Kumasaka MY, Yajima I, Iida M, Takahashi H, Inoue Y, Fukushima S, et al. Correlated expression levels of endothelin receptor B and Plexin C1 in melanoma. Am J Cancer Res. 2015;5(3):1117\u201323.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"1929_CR146","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/abbs\/gmx148","volume":"50","author":"Z Wang","year":"2018","unstructured":"Wang Z, Wang X, Zhou H, Dan X, Jiang L, Wu Y. Long non-coding RNA CASC2 inhibits tumorigenesis via the miR-181a\/PLXNC1 axis in melanoma. Acta Biochim Biophys Sin Shanghai. 2018;50(3):263\u201372. https:\/\/doi.org\/10.1093\/abbs\/gmx148.","journal-title":"Acta Biochim Biophys Sin Shanghai"},{"issue":"18","key":"1929_CR147","doi-asserted-by":"publisher","first-page":"8317","DOI":"10.1158\/0008-5472.CAN-04-4366","volume":"65","author":"I Roodink","year":"2005","unstructured":"Roodink I, Raats J, van der Zwaag B, Verrijp K, Kusters B, van Bokhoven H, et al. Plexin D1 expression is induced on tumor vasculature and tumor cells: a novel target for diagnosis and therapy? Cancer Res. 2005;65(18):8317\u201323. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-4366.","journal-title":"Cancer Res"},{"issue":"6","key":"1929_CR148","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/19336918.2016.1261785","volume":"10","author":"LA Meyer","year":"2016","unstructured":"Meyer LA, Fritz J, Pierdant-Mancera M, Bagnard D. Current drug design to target the Semaphorin\/Neuropilin\/Plexin complexes. Cell Adhes Migr. 2016;10(6):700\u20138. https:\/\/doi.org\/10.1080\/19336918.2016.1261785.","journal-title":"Cell Adhes Migr"},{"key":"1929_CR149","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fimmu.2020.00346","volume":"11","author":"V Iragavarapu-Charyulu","year":"2020","unstructured":"Iragavarapu-Charyulu V, Wojcikiewicz E, Urdaneta A. Semaphorins in angiogenesis and autoimmune diseases: therapeutic targets? Front Immunol. 2020;11:346. https:\/\/doi.org\/10.3389\/fimmu.2020.00346.","journal-title":"Front Immunol"},{"issue":"Suppl 5","key":"1929_CR150","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12920-020-0682-5","volume":"13","author":"X Zhang","year":"2020","unstructured":"Zhang X, Klamer B, Li J, Fernandez S, Li L. A pan-cancer study of class-3 semaphorins as therapeutic targets in cancer. BMC Med Genet. 2020;13(Suppl 5):45-020-0682-5. https:\/\/doi.org\/10.1186\/s12920-020-0682-5.","journal-title":"BMC Med Genet"},{"issue":"1","key":"1929_CR151","first-page":"17727\u2013019-54177","volume":"9","author":"L Jing","year":"2019","unstructured":"Jing L, Bo W, Yourong F, Tian W, Shixuan W, Mingfu W. Sema4C mediates EMT inducing chemotherapeutic resistance of miR-31-3p in cervical cancer cells. Sci Rep. 2019;9(1):17727\u2013019-54177-z.","journal-title":"Sci Rep"},{"issue":"1","key":"1929_CR152","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/0008-5472.CAN-20-1601","volume":"81","author":"LS Crump","year":"2021","unstructured":"Crump LS, Wyatt GL, Rutherford TR, Richer JK, Porter WW, Lyons TR. Hormonal regulation of Semaphorin 7a in ER(+) breast Cancer drives therapeutic resistance. Cancer Res. 2021;81(1):187\u201398. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1601.","journal-title":"Cancer Res"},{"issue":"3","key":"1929_CR153","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10456-012-9268-y","volume":"15","author":"H Zhou","year":"2012","unstructured":"Zhou H, Binmadi NO, Yang YH, Proia P, Basile JR. Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression. Angiogenesis. 2012;15(3):391\u2013407. https:\/\/doi.org\/10.1007\/s10456-012-9268-y.","journal-title":"Angiogenesis"},{"issue":"12","key":"1929_CR154","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/nm1505","volume":"12","author":"S Kaneko","year":"2006","unstructured":"Kaneko S, Iwanami A, Nakamura M, Kishino A, Kikuchi K, Shibata S, et al. A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord. Nat Med. 2006;12(12):1380\u20139. https:\/\/doi.org\/10.1038\/nm1505.","journal-title":"Nat Med"},{"issue":"15","key":"1929_CR155","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1242\/dev.01228","volume":"131","author":"T Miyashita","year":"2004","unstructured":"Miyashita T, Yeo SY, Hirate Y, Segawa H, Wada H, Little MH, et al. PlexinA4 is necessary as a downstream target of Islet2 to mediate slit signaling for promotion of sensory axon branching. Development. 2004;131(15):3705\u201315. https:\/\/doi.org\/10.1242\/dev.01228.","journal-title":"Development"},{"issue":"1","key":"1929_CR156","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/art.27243","volume":"62","author":"JS Kong","year":"2010","unstructured":"Kong JS, Yoo SA, Kim JW, Yang SP, Chae CB, Tarallo V, et al. Anti-neuropilin-1 peptide inhibition of synoviocyte survival, angiogenesis, and experimental arthritis. Arthritis Rheum. 2010;62(1):179\u201390. https:\/\/doi.org\/10.1002\/art.27243.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1929_CR157","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/19420862.2015.1102813","volume":"8","author":"TL Fisher","year":"2016","unstructured":"Fisher TL, Reilly CA, Winter LA, Pandina T, Jonason A, Scrivens M, et al. Generation and preclinical characterization of an antibody specific for SEMA4D. MAbs. 2016;8(1):150\u201362. https:\/\/doi.org\/10.1080\/19420862.2015.1102813.","journal-title":"MAbs"},{"issue":"4","key":"1929_CR158","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1158\/1535-7163.MCT-14-0924","volume":"14","author":"JE Leonard","year":"2015","unstructured":"Leonard JE, Fisher TL, Winter LA, Cornelius CA, Reilly C, Smith ES, et al. Nonclinical safety evaluation of VX15\/2503, a humanized IgG4 anti-SEMA4D antibody. Mol Cancer Ther. 2015;14(4):964\u201372. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0924.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"1929_CR159","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1158\/2326-6066.CIR-18-0156","volume":"7","author":"PE Clavijo","year":"2019","unstructured":"Clavijo PE, Friedman J, Robbins Y, Moore EC, Smith E, Zauderer M, et al. Semaphorin4D inhibition improves response to immune-checkpoint blockade via attenuation of MDSC recruitment and function. Cancer Immunol Res. 2019;7(2):282\u201391. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0156.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"1929_CR160","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/1078-0432.CCR-15-0431","volume":"22","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, et al. Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-Semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res. 2016;22(4):827\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0431.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1929_CR161","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10637-014-0071-z","volume":"32","author":"CD Weekes","year":"2014","unstructured":"Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, et al. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Investig New Drugs. 2014;32(4):653\u201360. https:\/\/doi.org\/10.1007\/s10637-014-0071-z.","journal-title":"Investig New Drugs"},{"issue":"5","key":"1929_CR162","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00280-014-2426-8","volume":"73","author":"A Patnaik","year":"2014","unstructured":"Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, et al. A phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014;73(5):951\u201360. https:\/\/doi.org\/10.1007\/s00280-014-2426-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1929_CR163","doi-asserted-by":"publisher","unstructured":"De Vlaeminck Y, Bonelli S, Awad RM, Dewilde M, Rizzolio S, Lecocq Q, et al. Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development. Cancers (Basel). 2020;12(12). https:\/\/doi.org\/10.3390\/cancers12123582.","DOI":"10.3390\/cancers12123582"},{"issue":"5","key":"1929_CR164","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2337\/db14-0719","volume":"64","author":"PK Aggarwal","year":"2015","unstructured":"Aggarwal PK, Veron D, Thomas DB, Siegel D, Moeckel G, Kashgarian M, et al. Semaphorin3a promotes advanced diabetic nephropathy. Diabetes. 2015;64(5):1743\u201359. https:\/\/doi.org\/10.2337\/db14-0719.","journal-title":"Diabetes"},{"key":"1929_CR165","first-page":"14\u20136606-7-14","volume":"7","author":"L Zhang","year":"2014","unstructured":"Zhang L, Kaneko S, Kikuchi K, Sano A, Maeda M, Kishino A, et al. Rewiring of regenerated axons by combining treadmill training with semaphorin3A inhibition. Mol Brain. 2014;7:14\u20136606-7-14.","journal-title":"Mol Brain"},{"issue":"11","key":"1929_CR166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047716","volume":"7","author":"M Omoto","year":"2012","unstructured":"Omoto M, Yoshida S, Miyashita H, Kawakita T, Yoshida K, Kishino A, et al. The semaphorin 3A inhibitor SM-345431 accelerates peripheral nerve regeneration and sensitivity in a murine corneal transplantation model. PLoS One. 2012;7(11):e47716. https:\/\/doi.org\/10.1371\/journal.pone.0047716.","journal-title":"PLoS One"},{"key":"1929_CR167","doi-asserted-by":"publisher","unstructured":"Imoto T, Kondo S, Wakisaka N, Hai PT, Seishima N, Kano M, et al. Overexpression of Semaphorin 3A is a Marker Associated with Poor Prognosis in Patients with Nasopharyngeal Carcinoma. Microorganisms. 2020;8(3). https:\/\/doi.org\/10.3390\/microorganisms8030423.","DOI":"10.3390\/microorganisms8030423"},{"issue":"14","key":"1929_CR168","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1242\/dev.00516","volume":"130","author":"W Shoji","year":"2003","unstructured":"Shoji W, Isogai S, Sato-Maeda M, Obinata M, Kuwada JY. Semaphorin3a1 regulates angioblast migration and vascular development in zebrafish embryos. Development. 2003;130(14):3227\u201336. https:\/\/doi.org\/10.1242\/dev.00516.","journal-title":"Development"},{"issue":"3","key":"1929_CR169","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/emmm.201100205","volume":"4","author":"A Casazza","year":"2012","unstructured":"Casazza A, Kigel B, Maione F, Capparuccia L, Kessler O, Giraudo E, et al. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. EMBO Mol Med. 2012;4(3):234\u201350. https:\/\/doi.org\/10.1002\/emmm.201100205.","journal-title":"EMBO Mol Med"},{"key":"1929_CR170","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.exer.2016.10.004","volume":"153","author":"S Toledano","year":"2016","unstructured":"Toledano S, Lu H, Palacio A, Kigel B, Kessler O, Allon G, et al. A SEMA3E mutant resistant to cleavage by furins (UNCL-SEMA3E) inhibits choroidal neovascularization. Exp Eye Res. 2016;153:186\u201394. https:\/\/doi.org\/10.1016\/j.exer.2016.10.004.","journal-title":"Exp Eye Res"},{"issue":"5","key":"1929_CR171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097950","volume":"9","author":"JT Nofiele","year":"2014","unstructured":"Nofiele JT, Cheng HL. Establishment of a lung metastatic breast tumor xenograft model in nude rats. PLoS One. 2014;9(5):e97950. https:\/\/doi.org\/10.1371\/journal.pone.0097950.","journal-title":"PLoS One"},{"key":"1929_CR172","doi-asserted-by":"publisher","unstructured":"Gioelli N, Maione F, Camillo C, Ghitti M, Valdembri D, Morello N, et al. A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent. Sci Transl Med. 2018;10(442). https:\/\/doi.org\/10.1126\/scitranslmed.aah4807.","DOI":"10.1126\/scitranslmed.aah4807"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-01929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-021-01929-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-01929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T08:01:51Z","timestamp":1724832111000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-021-01929-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":172,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1929"],"URL":"https:\/\/doi.org\/10.1186\/s13046-021-01929-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]},"assertion":[{"value":"8 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}